Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.

@article{Kreyenbuhl2011TimeTD,
  title={Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.},
  author={Julie Kreyenbuhl and Eric P. Slade and Deborah R. Medoff and C Hendricks Brown and Benjamin Ehrenreich and Joseph Afful and Lisa Beth Dixon},
  journal={Schizophrenia research},
  year={2011},
  volume={131 1-3},
  pages={127-32}
}
BACKGROUND Continuous adherence to antipsychotic treatment is critical for individuals with schizophrenia to benefit optimally, yet studies have shown rates of antipsychotic discontinuation to be high with few differences across medications. We investigated discontinuation of selected first- and second-generation antipsychotics among individuals with schizophrenia receiving usual care in a VA healthcare network in the U.S. mid-Atlantic region. METHODS We identified 2138 VA patients with… CONTINUE READING

4 Figures & Tables

Connections & Topics

Mentioned Connections BETA
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
SchizophreniaMay be treated byClozapine
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
SchizophreniaMay be treated byRisperidone
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
SchizophreniaMay be treated byolanzapine
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
Antipsychotic AgentsTherapeutic class ofClozapine
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
We identified 2138 VA patients with schizophrenia who initiated antipsychotic treatment with one of five non - clozapine second - generation antipsychotics or either of the two most commonly prescribed first - generation agents between 1/2004 and 9/2006 .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Antipsychotic AgentsTherapeutic class ofolanzapine
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
In multivariable analysis , only risperidone had a significantly greater hazard of discontinuation compared to olanzapine ( Adjusted hazard ratio=1.15 , 95% CI : 1.02 - 1.30 , p=.025 ) .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
In multivariable analysis , only risperidone had a significantly greater hazard of discontinuation compared to olanzapine ( Adjusted hazard ratio=1.15 , 95% CI : 1.02 - 1.30 , p=.025 ) .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
Examination of a usual care sample of individuals with schizophrenia revealed short durations of antipsychotic use , with only risperidone having a shorter time to discontinuation than olanzapine .
All Topics